CHARLESTON, S.C.--(BUSINESS WIRE)--Younis Zubchevich, Chief Executive Officer, with Zestra Laboratories Inc. (Zestra), announced in early November that enrollment of 200 women with mixed sexual dysfunctions had been completed for its voluntary clinical trial of Zestra® Feminine Arousal Fluid. This study takes an unprecedented look at the many factors influencing women’s sexual satisfaction. This is the second clinical study of non-prescription Zestra® and is designed to further determine its safety and effectiveness for increasing female sexual pleasure and satisfaction in diverse groups of women. This landmark study will also measure the effects of improved sexual experiences of women on both relationships and depression.
